<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00571129</url>
  </required_header>
  <id_info>
    <org_study_id>KUH5551812</org_study_id>
    <secondary_id>255104</secondary_id>
    <nct_id>NCT00571129</nct_id>
  </id_info>
  <brief_title>Endoscopic Dacryocystorhinostomy Prospective Research</brief_title>
  <official_title>Recovery After Endoscopic Dacryocystorhinostomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kuopio University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endoscopic dacryocystorhinostomy (EN-DCR) is an effective procedure when treating saccal and
      postsaccal obstructions of the nasolacrimal pathway. The benefit of silicone tubing after DCR
      is still controversial. We conducted a prospective, randomized study in order to evaluate 1)
      the necessity of bicanalicular silicone tubes after primary EN-DCR, 2) efficacy of the
      perioperative Mitomycin C for the prevention of adheesion and re-stenosis of rhinostomy site
      in revision EN-DCR, 3) the subjective symptoms and QoL changes before and after
      DCR-operation.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2004</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>DCR with/ without tubes Revision DCR with/ without mitomycin</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The success rate after primary DCR with and without silicone tubes. The success rate after revisio DCR with and without Mitomycin C.</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The EN-DCR operation influence on the patients subjective symptoms and QoL before and after operation.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Lacrimal Duct Obstruction</condition>
  <arm_group>
    <arm_group_label>with tubes or mitomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After DCR bicanalicular tubes were inserted After re-DCR mitomycin in cottonpads were placed into rhinostoma for 5 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>without tubes or mitomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After DCR no tubes were inserted After re-DCR no mitomycin was used</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DCR with no tubes or mitomycin</intervention_name>
    <description>The patients were randomized into the two study groups, either with or without the insertion of a bicanalicular silicone tube after primary DCR.
In revision group patients were randomized into the two groups,ether with or without application of mitomycin &quot;C&quot; after DCR</description>
    <arm_group_label>with tubes or mitomycin</arm_group_label>
    <arm_group_label>without tubes or mitomycin</arm_group_label>
    <other_name>DCR with tubes or mitomycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (age &gt; 18), ASAI-III, and were scheduled for primary or revision lacrimal
             pathway surgery due to recurrent or chronic watering eyes or conjunctival discharge.

          -  Patients were excluded if they had previous nasolacrimal surgery, malignancy in the
             paranasal sinuses, nasal cavity, or lacrimal pathway, presaccal obstruction, pregnancy
             or lactation, or mental disability.

        Exclusion Criteria:

          -  Malignancy in the paranasal sinuses, nasal cavity, or lacrimal pathway, presaccal
             obstruction, pregnancy or lactation, or mental disability.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juha Seppä, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Kuopio University Hospital, Otorhinolaryngology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <state>North-Savo</state>
        <zip>70210</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <reference>
    <citation>Penttilä E, Hyttinen JM, Hytti M, Kauppinen A, Smirnov G, Tuomilehto H, Seppä J, Nuutinen J, Kaarniranta K. Upregulation of inflammatory genes in the nasal mucosa of patients undergoing endonasal dacryocystorhinostomy. Clin Ophthalmol. 2014 Apr 25;8:799-805. doi: 10.2147/OPTH.S50195. eCollection 2014.</citation>
    <PMID>24851037</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 10, 2007</study_first_submitted>
  <study_first_submitted_qc>December 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2007</study_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kuopio University Hospital</investigator_affiliation>
    <investigator_full_name>Juha Seppa</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Primary,silicone tube,revision,mitomycin C,endoscopic DCR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacrimal Duct Obstruction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

